Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
1.700
+0.030 (1.80%)
At close: Feb 27, 2026, 4:00 PM EST
1.690
-0.010 (-0.59%)
After-hours: Feb 27, 2026, 7:51 PM EST
Daré Bioscience Revenue
Daré Bioscience had revenue of $2.26K in the quarter ending September 30, 2025, a decrease of -94.57%. This brings the company's revenue in the last twelve months to $-57.13K. In the year 2024, Daré Bioscience had annual revenue of $9.78K, down -99.65%.
Revenue (ttm)
$-57.13K
Revenue Growth
-99.65%
P/S Ratio
-425.21
Revenue / Employee
n/a
Employees
23
Market Cap
24.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.78K | -2.80M | -99.65% |
| Dec 31, 2023 | 2.81M | -7.19M | -71.92% |
| Dec 31, 2022 | 10.00M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 80.00K | 74.00K | 1,233.33% |
| Dec 31, 2013 | 6.00K | -619.00K | -99.04% |
| Dec 31, 2012 | 625.00K | 619.00K | 10,316.67% |
| Dec 31, 2011 | 6.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Neuphoria Therapeutics | 14.99M |
| Barinthus Biotherapeutics | 14.97M |
| Vistagen Therapeutics | 789.00K |
| Exicure | 500.00K |
| Hyperion DeFi | 345.32K |
DARE News
- 5 days ago - Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - GlobeNewsWire
- 2 months ago - DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility - GlobeNewsWire
- 3 months ago - Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns Transcript - Seeking Alpha
- 3 months ago - Daré Bioscience, Inc. (DARE) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025 - GlobeNewsWire
- 5 months ago - Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research - GlobeNewsWire
- 7 months ago - Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript - Seeking Alpha